| Literature DB >> 33116631 |
Di Huang1, Xue Chen1, Xuan Chen1, Yan Qu1, Yuanyuan Wang2, Yafei Yang3, Yufeng Cheng1.
Abstract
BACKGROUND: The WD40 protein family member WD repeat domain 5 (WDR5) plays significant roles in the tumorigenesis and development of multiple organ tumours. However, the correlation between WDR5 expression and oesophageal squamous cell carcinoma (ESCC) has not been elucidated.Entities:
Keywords: WDR5; oesophageal squamous cell carcinoma; prognosis; proliferation
Year: 2020 PMID: 33116631 PMCID: PMC7573303 DOI: 10.2147/OTT.S234773
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1(A) WDR5 mRNA expression data in ESCA acquired from TCGA. (B) Western blot analysis of WDR5 in 12 pairs of adjacent normal tissues and ESCC tissues. β-actin was employed as a loading control. (C) Representative immunohistochemical staining of WDR5 for ESCC tissues: low expression and high expression. (D) Kaplan–Meier curve for OS in ESCC (P=0.004).
The Correlations of Clinicopathologic Features of ESCC with WDR5 Expression in FFPE Cancerous Tissues
| Clinicopathological Features | WDR5 Overexpression | P- valuea | |
|---|---|---|---|
| NO(n=48) | YES(n=56) | ||
| Gender | 0.667 | ||
| Male | 36 | 44 | |
| Female | 12 | 12 | |
| Age, year | 0.164 | ||
| <60 | 20 | 31 | |
| ≥60 | 28 | 25 | |
| Drinking | 0.320 | ||
| NO | 32 | 32 | |
| YES | 16 | 24 | |
| Smoking | 0.585 | ||
| NO | 24 | 31 | |
| YES | 24 | 25 | |
| Differentiation | 0.084 | ||
| Well-moderate | 36 | 33 | |
| Poor | 12 | 23 | |
| TNM stage | |||
| I–II | 32 | 26 | |
| III–IV | 16 | 30 | |
| T stage | |||
| I–II | 29 | 22 | |
| III–IV | 19 | 34 | |
| N stage | 0.094 | ||
| 0 | 31 | 27 | |
| ≥1 | 17 | 39 | |
Notes: P-valuea, chi-square test; P-values in bold print are indicative of significant correlations.
Univariate and Multivariate Analyses Showing the Overall Survival in Esophageal Cancer
| Variables | OS | |||||
|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Gender (female vs male) | 0.225 | 0.458–1.392 | 0.799 | |||
| Age, year (<60 vs ≥60) | 0.527 | 0.370–0.942 | 0.590 | |||
| Drinking (YES vs NO) | 0.005 | 0.626–1.615 | 0.983 | |||
| Smoking (YES vs NO) | 0.141 | 0.545–1.383 | 0.869 | |||
| Differentiation (well + moderate vs poor) | 0.519 | 1.044–2.705 | 0.261 | 0.779–2.162 | 0.317 | |
| T stage (T1+T2 VS T3+T4) | 1.075 | 1.789–4.800 | 0.730 | 1.205–3.573 | ||
| N stage (negative vs positive) | 1.114 | 1.893–4.902 | 0.098 | 0.483–2.518 | 0.815 | |
| TNM stage (I–II vs III–IV) | 1.443 | 2.589–6.879 | 1.184 | 1.352–7.895 | ||
| WDR5 (low vs high) | 0.706 | 1.258–3.226 | 0.664 | 1.115–3.284 | ||
Note: The bold number represents the P-values with significant differences.
Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval.
Figure 2Downregulation effect of shWDR5 in vitro. (A) Expression of WDR5 protein in KYSE-150 and KYSE-140 cells were downregulated after shWDR5 transfection. (B) The result of the CCK-8 assay in ESCC cells. (C and D) The result of the colony formation assay in ESCC cells. (E) Cyclin D1 protein expression was examined by Western blot assay in KYSE-150 WDR5-downregulated cell lines. (F) The percentage of cells in Go/G1, S and G2/M phase from different groups. **, *** and **** represent P<0.01, P<0.001 and P<0.0001 respectively, between the indicated subgroups. Significance was calculated with Student’s t-test.
Figure 3Downregulation effect of shWDR5 in vivo. (A) Images of tumours from xenograft tumour models established with shWDR5 and its control cells. (B and C) Tumour weight and tumour volume statistical analysis of shWDR5 and its control cells. (D) Representative immunohistochemical staining of WDR5 for tumours from xenograft tumour models. (E) Representative immunohistochemical staining of Ki-67 for tumours from xenograft models. ** and *** represent P<0.01 and P<0.001 respectively, between the indicated subgroups.
Figure 4Effects of WDR5 on the PI3K/AKT/mTOR pathway in ESCC. (A) Western blot was performed to measure the expression of WDR5 and PI3K/AKT/mTOR pathway markers. (B) p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR, p-P70S6K/P70S6K, and p-S6/S6 expression ratios in shNC and shWDR5. * and ** represent P<0.05, P<0.01 respectively, between the indicated subgroups.